ホーム › 卵巣がん › ミネソタ州 › Rochester
Rochester、MNにおける卵巣がんの臨床試験
Rochesterとその周辺地域（約30マイル以内）の拠点で、卵巣がんに関する29件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
被験者募集中第2/3相
- Mayo Clinic in Rochester, Rochester
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- Mayo Clinic in Rochester, Rochester
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
被験者募集中観察研究
- Mayo Clinic, Rochester
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
被験者募集中
- Mayo Clinic, Rochester
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
被験者募集中観察研究
- Mayo Clinic Rochester, Rochester
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
被験者募集中第1/2相
- Mayo Clinic - Rochester, Rochester
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
被験者募集中第3相
- Mayo Clinic in Rochester, Minnesota, Rochester
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
被験者募集中第1相
- Mayo Clinic - Rochester, Rochester
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
被験者募集中第1/2相
- Mayo Rochester, Rochester
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
被験者募集中観察研究
- Mayo Clinic (Rochester), Rochester
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
被験者募集中
- Mayo Clinic in Rochester, Rochester
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
被験者募集中第3相
- Mayo Clinic in Rochester, Rochester
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Mayo Clinic (Minnesota), Rochester
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
被験者募集中第3相
- Mayo Clinic Methodist Campus, Rochester
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
被験者募集中第2相
- Mayo Clinic, Rochester
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
被験者募集中第1/2相
- The Mayo Clinic, Rochester
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
被験者募集中第1相
- Mayo Clinic, Rochester
Lead-212 PSV359 Therapy for Patients With Solid Tumors
被験者募集中第1/2相
- Mayo Clinic in Rochester, Minnesota, Rochester
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
被験者募集中第1/2相
- Mayo Clinic - Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
被験者募集中第1/2相
- Mayo Clinic Rochester, Rochester
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
被験者募集中
- Mayo Clinic, Rochester
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
被験者募集中第3相
- Mayo Clinic, Rochester
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
被験者募集中
- Mayo Clinic, Rochester
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
被験者募集中第1/2相
- Mayo Clinic, Rochester
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
被験者募集中第1相
- Mayo Clinic in Rochester, Rochester
Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions
被験者募集中
- Mayo Clinic in Rochester, Rochester
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
被験者募集中観察研究健康なボランティア歓迎
- Mayo Clinic, Rochester
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
被験者募集中第2相
- Mayo Clinic, Rochester
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #14, Rochester
他の都市における卵巣がんの試験
- Houston, TX89件の研究
- New York City, NY69件の研究
- Boston, MA61件の研究
- Los Angeles, CA50件の研究
- Nashville, TN49件の研究
- Arlington, VA46件の研究
- Philadelphia, PA44件の研究
- Columbus, OH39件の研究
- St. Louis, MO38件の研究
- Chicago, IL36件の研究
- San Antonio, TX31件の研究
- Cleveland, OH30件の研究
Rochesterにおける他の研究
- 乳がん42件の研究
- 非小細胞肺癌37件の研究
- 転移性癌31件の研究
- がん（全種類）30件の研究
- 大腸癌29件の研究
- 多発性骨髄腫24件の研究
- 心不全22件の研究
- 前立腺がん22件の研究
- 膵臓がん22件の研究
- 子宮内膜がん20件の研究
- 肺がん20件の研究
- 慢性リンパ性白血病18件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。